Bengaluru, December 12, 2015: In case of export of drugs, Indian pharmaceutical companies are required to comply with the regulatory provisions of the importing country. Isolated reports of the drugs not meeting the prescribed standards have appeared in the media and on the websites of the regulatory authorities of foreign countries etc. from time to time. As per recent media reports, regulatory action has been taken by USFDA against nine Indian pharmaceutical companies. Such instances impact our exports only marginally.
The gaps and weaknesses of our regulatory structures have been identified and the Government has, with a view to strengthen the regulatory regime, approved a proposal to strengthen the drug regulatory structures both at the Centre and in the States at a total cost of Rs.1750/- crore. The strengthening will include construction of new offices and laboratories, re-equipping existing laboratories, additional manpower, training, e-governance modules and IT infrastructure.
With a view to raise the credibility of our drugs, the Department of Commerce has introduced bar coding on secondary and tertiary packs for exports for tracking and tracing the medicines. Once fully implemented, it will remove the chances of someone else selling medical products that are not genuine.
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…